SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Steinberg Peter))
 

Search: (WFRF:(Steinberg Peter)) > Impact of dronedaro...

  • Handelsman, YehudaMetabolic Institute of America (author)

Impact of dronedarone on patients with atrial fibrillation and diabetes : A sub-analysis of the ATHENA and EURIDIS/ADONIS studies

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • Elsevier BV,2022

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:b535c37a-7a5e-4385-9191-a979b01fb6a4
  • https://lup.lub.lu.se/record/b535c37a-7a5e-4385-9191-a979b01fb6a4URI
  • https://doi.org/10.1016/j.jdiacomp.2022.108227DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Aim: This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes. Methods: Patients were categorized according to baseline diabetes status. Time-to-event analyses were performed using Kaplan-Meier method. Hazard-ratios were assessed using Cox models. Results: 945/4628 (dronedarone = 482; placebo = 463) patients in ATHENA and 215/1237 (dronedarone = 148; placebo = 67) patients in EURIDIS/ADONIS studies had diabetes. In ATHENA, there were higher rates of CV hospitalization/death in patients with diabetes (39.5%) than without diabetes (34.7%). Incidence of first CV hospitalization/death was lower in patients with diabetes treated with dronedarone (35.1%) than placebo (44.1%), and time to this event was longer in those treated with dronedarone than placebo (log-rank p = 0.005). Median AF/AFL recurrence time was longer in patients treated with dronedarone than placebo in patients with diabetes (ATHENA: 722 vs 527 days, log-rank p = 0.004; EURIDIS/ADONIS: 100 vs 23 days, log-rank p = 0.15) or without diabetes (ATHENA: 741 vs 492 days, log-rank p < 0.0001; EURIDIS/ADONIS: 120 vs 59 days, log-rank p = 0.0002). Occurrence of any treatment-related adverse events with dronedarone was similar for patients with/without diabetes and was comparable to placebo. Conclusions: Dronedarone reduced incidence of CV hospitalization/death, AF/AFL recurrence and increased time to these events in AF/AFL patients with/without diabetes. Trial registration: Not applicable, as it was a post hoc analysis. This article is based on previously conducted studies (ATHENA: NCT00174785, EURIDIS: NCT00259428, and ADONIS: NCT00259376).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bunch, T. JaredUniversity of Utah (author)
  • Rodbard, Helena W.Endocrine and Metabolic Consultants (author)
  • Steinberg, Benjamin A.University of Utah (author)
  • Thind, MunveerLankenau Institute for Medical Research (author)
  • Bigot, GregoryIVIDATA (author)
  • Konigsberg, LanaSanofi US Services Inc. (author)
  • Wieloch, MattiasLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups,Sanofi S.A., France(Swepub:lu)medf-mwi (author)
  • Kowey, Peter R.Lankenau Institute for Medical Research (author)
  • Metabolic Institute of AmericaUniversity of Utah (creator_code:org_t)

Related titles

  • In:Journal of Diabetes and its Complications: Elsevier BV36:71056-8727

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view